INCB 54828

Drug Profile

INCB 54828

Alternative Names: INCB 054828; INCB54828

Latest Information Update: 17 Mar 2017

Price : $50

At a glance

  • Originator Incyte Corporation
  • Class Antineoplastics
  • Mechanism of Action Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cholangiocarcinoma; Lymphoid leukaemia; Myeloid leukaemia; Urogenital cancer
  • Phase I/II Multiple myeloma; Solid tumours

Most Recent Events

  • 26 Dec 2016 Phase-II clinical trials in Lymphoid leukaemia (Second-line therapy or greater) in USA (PO) (NCT03011372)
  • 26 Dec 2016 Phase-II clinical trials in Myeloid leukaemia (Second-line therapy or greater) in USA (PO) (NCT03011372)
  • 30 Nov 2016 Incyte Corporation plans a phase II trial for Myeloid leukaemia and Lymphoid leukaemia (Monotherapy, Second-line therapy or greater) in USA, Austria, France, Germany, Italy, Spain, Switzerland and United Kingdom (PO) (NCT03011372)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top